Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 14/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444394 | 0.81 | AR (0.50) | ARPOLB | |
| SCHEMBL16702383 | 0.76 | AR (0.54) | OPRL1ARPOLBL3MBTL1CMA1 | |
| SCHEMBL5946591 | 0.76 | OPRL1 (0.61) | OPRL1LIPE | |
| SCHEMBL5946590 | 0.76 | OPRL1 (0.61) | OPRL1LIPE | |
| SCHEMBL16264819 | 0.74 | AR (0.52) | OPRL1ARPOLBL3MBTL1CMA1 | |
| SCHEMBL17912958 | 0.74 | AR (0.52) | OPRL1ARPOLBL3MBTL1CMA1 | |
| SCHEMBL25391026 | 0.74 | POLB (0.42) | OPRL1POLBL3MBTL1LIPE | |
| SCHEMBL6177616 | 0.74 | LIPE (0.46) | OPRL1POLBL3MBTL1LIPE | |
| SCHEMBL15533490 | 0.73 | POLB (0.46) | OPRL1POLBL3MBTL1LIPENR1H4 | |
| SCHEMBL19094530 | 0.72 | OPRL1 (1.00) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181261-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2858501-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013176970-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | NGF, NGFR, NTRK1 | OPRL1 211/4885AR 2303/4885POLB 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.